Efficacy of neoadjuvant chemotherapy on prognosis of muscle-invasive bladder cancer: a Meta-analysis study

樊晓栋; 姜庆; 王家武

您当前的位置：

首页 >

文章列表页 >

Efficacy of neoadjuvant chemotherapy on prognosis of muscle-invasive bladder cancer: a Meta-analysis study

更新时间：2026-01-09

- Efficacy of neoadjuvant chemotherapy on prognosis of muscle-invasive bladder cancer: a Meta-analysis study
- Journal of Army Medical University Vol. 33, Issue 2, Pages: 196-199(2011)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R195.1;R730.53;R737.14
- Published：2011
- 稿件说明：
移动端阅览
樊晓栋,姜庆,王家武.新辅助化疗对肌层浸润性膀胱癌预后影响的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2011,33(02):196-199.

　Fan Xiaodong,Jiang Qing,Wang Jiawu.Efficacy of neoadjuvant chemotherapy on prognosis of muscle-invasive bladder cancer: a Meta-analysis study[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(02):196-199.
樊晓栋,姜庆,王家武.新辅助化疗对肌层浸润性膀胱癌预后影响的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2011,33(02):196-199. DOI：

　Fan Xiaodong,Jiang Qing,Wang Jiawu.Efficacy of neoadjuvant chemotherapy on prognosis of muscle-invasive bladder cancer: a Meta-analysis study[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(02):196-199. DOI：

摘要

目的评价新辅助化疗对肌层浸润性膀胱癌患者预后的影响。方法通过PubMed、Cochrane library、万方、康健、CBMdisc、EMBASE等数据库收集国内外已发表的相关前瞻性随机对照研究，按预设的标准进行筛选，共12个研究符合纳入标准，总样本量3 286例，新辅助治疗组1 636例，对照组1 650例，对纳入研究进行质量评价，并提取数据进行Meta分析。结果新辅助化疗组与对照组相比，死亡风险优势比0.85（95% CI 0.73～0.98，P=0.03）。将12个纳入研究按新辅助化疗方案进行亚组分析，单用铂剂组显示新辅助化疗并没有降低患者死亡风险，而以铂剂为基础的多药联合新辅助化疗可降低患者死亡风险（OR 0.79，95% CI 0.67～0.92，P=0.000 4）。结论新辅助化疗，尤其是以铂剂为基础的联合化疗方案，适用于肌层浸润性膀胱癌的治疗，可改善预后。

Abstract

Objective To evaluate the effect of neoadjuvant chemotherapy on the prognosis of muscle-invasive bladder cancer. Methods Published prospective randomized controlled trials (RCT) on neoadjuvant chemotherapy for muscle-invasive bladder cancer were searched and screened in Pubmed

EMBASE

CBMdisc

Cochrane library and Wanfang databases under preset standards. The data from eligible studies were pooled through Meta-analysis. Results Totally 12 trials including 3 286 patients were eligible to the criteria (1 636 in study group and 1 650 in control group).The odds radio of all trails tended to favour neoadjuvant chemotherapy (OR=0.85

95% CI 0.73 to 0.98

P=0.03). Platinum-based combination chemotherapy showed a significant reduction in risk of death（OR=0.79

95% CI=0.67 to 0.92

P=0.0004)

but there was no evidence to support the use of single-agent platinum. Conclusions Neoadjuvant chemotherapy especially platinum-based combination chemotherapy is beneficial to muscle-invasive bladder cancer patients.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Development and validation of a prediction model for amputation risk in patients with diabetic foot ulcers based on systematic review and meta-analysis

Effect of Del Nido cardioplegia solution on myocardial protection in adult cardiac surgery under cardiopulmonary bypass: a Meta-analysis

Influencing factors and efficacy prediction of neoadjuvant chemotherapy for ER positive breast cancer

Levels of alanine aminotransferase and aspartate aminotransferase in coronavirus disease 2019 patients: a meta-analysis

Diagnostic value of whole body 18F-FDG PET/CT imaging in metastatic cancer of unknown primary: a Meta-analysis

Related Author

HAN Weidong

FAN Yiming

CHEN Pan

HU Nan

HU Shiqi

XIONG Te

YIN Rui

徐旭

Related Institution

Department of Dermatology， First Affiliated Hospital， Army Medical University （Third Military Medical University）

⁰